Adaptive Biotechnologies (ADPT) Competitors $11.98 +0.50 (+4.32%) Closing price 03:56 PM EasternExtended Trading$12.03 +0.05 (+0.45%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADPT vs. LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, AKRO, PCVX, and ADMAShould you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Adaptive Biotechnologies vs. Its Competitors Legend Biotech TG Therapeutics Grifols Lantheus Telix Pharmaceuticals Nuvalent Axsome Therapeutics Akero Therapeutics Vaxcyte ADMA Biologics Legend Biotech (NASDAQ:LEGN) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Which has higher earnings and valuation, LEGN or ADPT? Adaptive Biotechnologies has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLegend Biotech$627.24M10.36-$177.03M-$0.59-59.92Adaptive Biotechnologies$178.96M10.17-$159.49M-$0.96-12.48 Which has more volatility and risk, LEGN or ADPT? Legend Biotech has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Do analysts prefer LEGN or ADPT? Legend Biotech presently has a consensus target price of $72.60, indicating a potential upside of 105.37%. Adaptive Biotechnologies has a consensus target price of $10.57, indicating a potential downside of 11.73%. Given Legend Biotech's stronger consensus rating and higher possible upside, equities analysts plainly believe Legend Biotech is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Do insiders & institutionals have more ownership in LEGN or ADPT? 70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is LEGN or ADPT more profitable? Legend Biotech has a net margin of -29.95% compared to Adaptive Biotechnologies' net margin of -74.84%. Legend Biotech's return on equity of -21.19% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Legend Biotech-29.95% -21.19% -13.47% Adaptive Biotechnologies -74.84%-62.79%-24.55% Does the media prefer LEGN or ADPT? In the previous week, Legend Biotech had 1 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for Legend Biotech and 7 mentions for Adaptive Biotechnologies. Legend Biotech's average media sentiment score of 0.59 beat Adaptive Biotechnologies' score of 0.53 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLegend Biotech beats Adaptive Biotechnologies on 11 of the 16 factors compared between the two stocks. Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADPT vs. The Competition Export to ExcelMetricAdaptive BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.74B$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-12.4821.4227.3820.03Price / Sales10.17281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book8.747.518.085.67Net Income-$159.49M-$55.05M$3.16B$248.47M7 Day Performance-1.51%3.16%2.12%2.90%1 Month Performance20.48%5.92%4.43%5.75%1 Year Performance253.27%5.82%35.62%21.36% Adaptive Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADPTAdaptive Biotechnologies3.4511 of 5 stars$11.98+4.3%$10.57-11.7%+240.7%$1.74B$178.96M-12.48790News CoverageGap UpLEGNLegend Biotech3.2538 of 5 stars$33.85-0.4%$76.20+125.1%-19.7%$6.22B$627.24M-57.372,609News CoverageAnalyst ForecastTGTXTG Therapeutics3.1627 of 5 stars$36.56+1.5%$40.80+11.6%+98.2%$5.80B$329M152.33290GRFSGrifols4.0481 of 5 stars$8.37-4.6%$10.30+23.1%+40.2%$5.75B$7.81B7.1523,822LNTHLantheus4.4515 of 5 stars$80.81+2.0%$130.50+61.5%+1.4%$5.59B$1.53B22.96700TLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.54B$516.72M0.00N/ANews CoverageAnalyst ForecastGap DownHigh Trading VolumeNUVLNuvalent3.7365 of 5 stars$75.98+1.3%$115.50+52.0%+10.3%$5.46BN/A-17.3140Analyst UpgradeInsider TradeAXSMAxsome Therapeutics4.6533 of 5 stars$101.65+1.0%$172.33+69.5%+31.6%$5.01B$385.69M-17.62380Analyst ForecastAnalyst RevisionAKROAkero Therapeutics3.7421 of 5 stars$54.03-0.3%$82.50+52.7%+131.8%$4.31BN/A-27.7130Insider TradePCVXVaxcyte1.7733 of 5 stars$33.25+1.2%$136.50+310.5%-56.3%$4.29BN/A-8.33160News CoveragePositive NewsADMAADMA Biologics4.2112 of 5 stars$17.87+0.7%$27.67+54.8%+59.1%$4.27B$426.45M21.02530 Related Companies and Tools Related Companies Legend Biotech Competitors TG Therapeutics Competitors Grifols Competitors Lantheus Competitors Telix Pharmaceuticals Competitors Nuvalent Competitors Axsome Therapeutics Competitors Akero Therapeutics Competitors Vaxcyte Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADPT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADPT Stock Alerts